Sep 26, 2023 / 08:55PM GMT
Jennifer M. Kim - Cantor Fitzgerald & Co., Research Division - Biopharma & Biotech Analyst
Our final fireside chat of the day. I'm Jennifer Kim, a biopharma and biotech analyst here at Cantor. And I'm looking forward to hosting Helen Sabzevari, President and CEO of Precigen. Helen, thanks for joining us.
Helen Sabzevari - Precigen, Inc. - President, CEO & Director
Thank you for having us.
Questions and Answers:
Jennifer M. Kim - Cantor Fitzgerald & Co., Research Division - Biopharma & Biotech AnalystOkay. Maybe we can start. Could you give a brief introduction of yourself and Precigen?
Helen Sabzevari - Precigen, Inc. - President, CEO & Director
Sure. I'm Helen Sabzevari. As you mentioned, I'm the CEO and President of Precigen. And Precigen is a biotech company that focuses on cell and gene therapy that it specifically addresses the Precigen medicine by activating the immune system in various fashion and different indications.